RARE Daily

Deep Genomics Boasts an AI First in Drug Discovery

October 11, 2019

Last month, Deep Genomics garnered headlines when it declared that it had nominated the industry’s first artificial intelligence-discovered therapeutic candidate. The experimental therapy is intended to treat Wilson disease, a rare and potentially life-threatening condition. The target for the therapy was also identified by the company’s AI platform and Deep Genomics said it was able to identify the target and drug candidate in less than 18 months. We spoke to Brendan Frey, founder and CEO of Deep Genomics, about the company’s AI platform, why it is focused on genetic disease, and the case for the company’s approach to drug discovery.A

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube